CBD is becoming increasingly popular among people of all ages, for both medical and general health and well-being. This is the first published survey that specifically analyzes users of CBD, as opposed to users of cannabis or medical cannabis in general. The results of this study suggest that CBD is more often used as a specific therapy for medical conditions than for recreational or non-medical reasons. The use of CBD is widespread, with people learning about it through the Internet, friends or family, rather than from health professionals.
It is used as a specific therapy for a number of diverse medical conditions, such as pain and inflammatory disorders, anxiety, depression and sleep disorders. A large percentage of respondents indicate that CBD treats their condition(s) effectively in the absence of conventional medications and with non-serious adverse effects. Approval of CBD for the treatment of Lennox-Gastaut syndrome and Dravet syndrome has revolutionized the lives of patients and their families. It is easily obtainable in most parts of the United States, although its exact legal status has been changing.
Medical users were more likely to learn about CBD from a doctor or naturopathic doctor and to use it more often than those who used it for general health and well-being. Non-serious adverse effects were relatively common among respondents and higher among those using CBD for general health and well-being. In the future, CBD may have therapeutic benefits for a variety of medical conditions, from arthritis to depression. The half-life of CBD after oromucosal spraying is between 1.4 and 10.9 hours, 2 and 5 days after chronic oral consumption and 31 hours after smoking. In addition, the use of THC has been linked to anxiety and increased heart rate, but these symptoms have not been found in volunteers in CBD trials. CBD products can currently be purchased online, without a prescription and at specific cannabis dispensaries in most parts of the country, despite the fact that CBD is generally considered a Schedule I controlled substance by the U.
S. government. Reports of negative reactions to pure CBD are very few and far between, but researchers can say that the cannabinoid would not be the only culprit. Eighty-one respondents were excluded from the analysis for not answering the first question about reported use of CBD, leaving 2,409 respondents included in the final study population. Currently, CBD has only been approved for children two years of age and older who suffer from seizure disorders Lennox-Gastaut syndrome and Dravet syndrome.
